Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Active not recruiting 5Recruiting 3Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Thyroid Neoplasms 1Neoplasm Metastasis 1Melanoma 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Advanced Malignancies 1

Interventions

Specimen Handling 311Magnetic Resonance Spectroscopy 266pembrolizumab 251Carboplatin 184Cyclophosphamide 176Biopsy 172Cisplatin 157Gemcitabine 134Paclitaxel 131Bevacizumab 124fludarabine 117Radiotherapy 108Nivolumab 108Oxaliplatin 88Docetaxel 87Fluorouracil 85Capecitabine 83venetoclax 82Dexamethasone 77Pemetrexed 72Rituximab 71Leucovorin 69Drug Therapy 69atezolizumab 67durvalumab 66Radiosurgery 65Blood Specimen Collection 65Standard of Care 63Doxorubicin 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Midazolam × 90 days × Clear all
NCT05355701 2026-06-05

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Pfizer

Phase 1 Recruiting
267 enrolled
CNSDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

NCT07426757 2026-06-01

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Pfizer

Phase 1 Recruiting
120 enrolled

Advanced Malignancies

NCT05384626 2026-05-27

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Nuvalent Inc.

Phase 1/2 Recruiting
840 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡